Literature DB >> 26188536

Airflow obstruction was associated with elevation of brachial-ankle pulse wave velocity but not ankle-brachial index in aged patients with chronic obstructive pulmonary disease.

Rui Chen1, Wanbing He2, Kun Zhang2, Houzhen Zheng1, Lin Lin1, Ruqiong Nie2, Jingfeng Wang2, Hui Huang3.   

Abstract

OBJECTIVE: Both brachial-ankle pulse wave velocity (baPWV) and ankle-brachial index (ABI) are important predictors for cardiovascular disease (CVD). Patients with chronic obstructive pulmonary disease (COPD) are at high risk of CVD. But the association between airflow obstruction and baPWV or ABI was still unclear. The study was aimed to investigate the influencing factors on arterial stiffness in aged COPD patients.
METHODS: 67 aged patients with COPD and 67 age- and sex-matched controls without COPD were enrolled in this study. COPD patients were grouped into four groups according to the Global Initiative for Chronic Obstructive Lung Disease Guidelines (GOLD). Both baPWV and ABI were evaluated. Spirometry indices, blood pressure, smoking history and related laboratory parameters were also collected.
RESULTS: Comparing with controls, all COPD patients had significantly higher baPWV (1933 ± 355 cm/s versus 1515 ± 256 cm/s, P < 0.001) but not ABI (P = 0.196). And baPWV values were significantly highest at GOLD stage 4. Forced expiratory volume in 1 s (FEV1) was the most significant factor influencing baPWV, after adjusting for age, systolic blood pressure and other traditional cardiovascular risk factors (β = -0.463, P = 0.014).
CONCLUSION: Arterial stiffness was serious in aged patients with COPD. Spirometry index FEV1 was a possible important predictor for the severity of arterial stiffness of COPD patients.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Aged; Ankle-brachial index; Brachial-ankle pulse wave velocity; Chronic obstructive pulmonary disease; Force expiratory volume in 1 s

Mesh:

Year:  2015        PMID: 26188536     DOI: 10.1016/j.atherosclerosis.2015.06.052

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.

Authors:  Surya P Bhatt; Mark T Dransfield; John R Cockcroft; Jie Wang-Jairaj; Dawn A Midwinter; David B Rubin; Catherine A Scott-Wilson; Courtney Crim
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-01-19

2.  Apocynin attenuates angiotensin II-induced vascular smooth muscle cells osteogenic switching via suppressing extracellular signal-regulated kinase 1/2.

Authors:  Weijing Feng; Kun Zhang; Yu Liu; Jie Chen; Qingqing Cai; Yinyin Zhang; Mongheng Wang; Jingfeng Wang; Hui Huang
Journal:  Oncotarget       Date:  2016-12-13

3.  Effect of Bronchodilator and Steroid Use on Heart Disease and Stroke Risks in a Bronchiectasis-Chronic Obstructive Pulmonary Disease Overlap Cohort: A Propensity Score Matching Study.

Authors:  Jun-Jun Yeh; Yu-Cih Yang; Chung Y Hsu; Chia-Hung Kao
Journal:  Front Pharmacol       Date:  2019-11-27       Impact factor: 5.810

4.  Arterial stiffness in adults with steady-state bronchiectasis: association with clinical indices and disease severity.

Authors:  Yong-Hua Gao; Juan-Juan Cui; Ling-Yun Wang; Ke-Qin Yin; Li Wang; Guo-Jun Zhang; Shao-Xia Liu
Journal:  Respir Res       Date:  2018-05-09

5.  Does peripheral arterial occlusive disease influence muscle strength and exercise capacity in COPD patients?

Authors:  Natacha Angélica da Fonseca Miranda; Cássia da Luz Goulart; Audrey Borghi E Silva; Dannuey Machado Cardoso; Dulciane Nunes Paiva; Renata Trimer; Andréa Lúcia Gonçalves da Silva
Journal:  J Vasc Bras       Date:  2017 Oct-Dec

6.  Warfarin Accelerates Aortic Calcification by Upregulating Senescence-Associated Secretory Phenotype Maker Expression.

Authors:  Ningle Wei; Liuyi Lu; Huanji Zhang; Ming Gao; Sounak Ghosh; Zhaoyu Liu; Junhua Qi; Jingfeng Wang; Jie Chen; Hui Huang
Journal:  Oxid Med Cell Longev       Date:  2020-10-22       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.